Side-effects of chemotherapy
Chemotherapy often causes serious side effects, limiting its ability to treat cancer. Side effects are a consequence of off-target drug uptake of these toxic agents in healthy tissues.
Tumor-targeted drug delivery
While antibody-drug conjugates show the benefits of targeted delivery, antibodies target very rare molecular biomarkers, limiting the benefits of this technology to just a few cancers. Most patients still rely on untargeted therapies.
A universal cancer biomarker
Tumor acidity provides a biomarker for targeted drug delivery to 95% of cancers. Acidity is an unavoidable consequence of the way cancers grow and metabolize that is universal to solid tumors.
A small-molecule tumor-targeted platform
Cytosolix has a unique approach to improve existing therapeutics that is applicable to most classes of small molecule drugs.
Targets drug-delivery to an unexploited, newly-validated biomarker universal to solid tumors - 95% of cancers.
Improved safety and therapeutic index enables more intensive therapy and better outcomes with lower side effects.
John C. Deacon, Ph.D.
Founder and President
Associate Research Scientist, Yale School of Medicine
Colin Foster, M.B.A.
Formerly CEO, Bayer North America
Wayne Klohs, Ph.D.
Formerly Senior VP Global Oncology, Astellas
Formerly Head of Oncology, Pfizer
Terrence Doyle, Ph.D.
Formerly Director of Preclinical Cancer Research, BMS
Formerly CSO, Vion Pharmaceuticals
J. Paul Eder, M.D.
Director Phase I Program, Yale Cancer Center
Formerly Medical Science Director, AstraZeneca
Stephen Sasson Ph.D.
Formerly VP World Regulatory Affairs, and Clinical & Medical Sciences Team Leader, Pfizer
The Cytosolix Opportunity
Our approach achieves up to 100-fold improvements without changing the active agent
Preclinical examples show that our core concept translates to therapeutic outcomes
Our platform can bring first-in-class targeted therapies to new indications, addressing unmet clinical needs
Our platform can be applied to nearly every class of small molecule chemotherapy
Targeting tumor acidity can be built into drug discovery in oncology - revolutionizing the next generation of chemotherapy
Cytosolix is positioned to lead the industry into a new era of tumor-targeted drug-delivery